

Genome Editing **Applications**

Therapeutic and Biomedical Applications of CRISPRs, ZFNs, TALENs and other Genome **Editing Techniques**

3 - 4 February 2016 | Sheraton Airport Hotel | Brussels | Belgium

Event Home 🔽 Programme 🖸 Workshops 🔯 Present a Poster | Sponsorship 🔯 Accommodation 🔯 Content 🔯



Programme (Updated 25 December 2015)

Register Now

Subscribe to

e-Mail / SMS Alerts









Accelerate your Therapeutics to Market and Improve Drug Discovery Efficiencies

Uncover Ways to Navigate the IP Landscape of Genome **Editing Technologies**

EVENT IS DEFERRED

Due to the latest advice available and the 'special circumstances' currently in place in Brussels, we regretfully inform all participants that the Genome Editing Applications event will be deferring until 3rd-4th February 2016 in the same venue.

Book Your Exhibition Space For 2016

Contact finda.cole@informa.com to book your space now to avoid disappointment

Therapeutic and Biomedical Applications of CRISPRs, ZFNs, TALENs and other Genome Engineering **Technologies**

Therapeutic, Drug Discovery & Research Applications of Genome Editing Technologies

Informa's Genome Editing conference will showcase the most up-to-date therapeutic and biomedical applications emerging using CRISPRs, ZFNs, TALENs, AAVs and other genome engineering technologies. From improving lead discovery, validation of targeted cell lines and development of transgenic animal models to therapeutic uses in cell therapy & gene therapy.

A special emphasis on CRISPR will highlight the design of novel CRISPR constructs and discuss practical aspects of CRISPR including monitoring off-target effects, strategies to improve specificity and delivery to specific cell types, including potential applications in multigenic alterations.

By attending this applications focused conference you will learn about advances in all of the latest genome editing technologies and how to position your company for success in genome editing in the face of the stillevolving IP landscape of CRISPR.

Feedback from our USA Genome Editing Event

2016 Speaker Faculty

- Lorenz Mayr, AstraZeneca, UK
- TJ Cradick, CRISPR Therapeutics, USA
- Philippe Duchateau, Cellectis, France
- Ines Royaux, Janssen R&D, a division of Janssen Pharmaceutica NV, Belgium
- Myung Shin, Merck & Co., Inc. USA
- · Anett Ritter, Novartis, Switzerland
- William Skarnes, The Wellcome Trust Sanger Institute, UK
- Roderick Beijersbergen, The Netherlands Cancer Institute, The Netherlands
- Helene Faustrup Kildegaard, Technical University of Denmark, Denmark
- Paul Diehl, Cellecta, Inc., USA
- Laurakay Bruhn, Agilent Research Labs, USA
- Victor Dillard, Desktop Genetics, UK
- Rafael Yáñez-Muñoz, Royal Holloway-University of London, UK
- Phillip Webber, Dehns (Patent and Trade Mark Attorneys), UK
- · Eric Paul Bennett, University of Copenhagen, Denmark

Dates and Venues

03 Feb 2016 - 04 Feb 2016

Sheraton Brussels Airport Hotel

2016 Sponsors & Exhibitors



Co-located with

Cell Therapy Manufacturing &GeneTherapy

CONGRESS

Who Should Attend Genome Editing 2015?

- Target Discovery
- Target Identification
- Target Validation
- Genomics / Genetics
- Genome Editing / Gene Editing
- Genome Engineering

Genome Editing **Applications**

Therapeutic and Biomedical Applications of CRISPRs, ZFNs, TALENs and other Genome **Editing Techniques**

3 - 4 February 2016 | Sheraton Airport Hotel | Brussels | Belgium

Event Home 🔽 Programme 🔽 Workshops 🔽 Present a Poster | Sponsorship 🔽 Accommodation 🔽 Content 🔽

Pre-Conference Workshop

Pre-Conference Workshop: Tuesday 2nd February 2016

Innovative Approaches to Characterise and Enhance the Specificity of **CRISPR/Cas9 Systems**

Registration 10:00 - Start 10:30 - End no later than 16:30. Refreshments and lunch will be provided.

This full day workshop will focus on exploring innovative approaches for defining and improving the specificity of CRISPR/Cas9 systems.

Those who attend will benefit from an interactive format covering a range of topics including:

- Latest efforts to define, study and characterise the function and specificity of CRISPR
- Strategies to modify, improve and overcome the main challenges surrounding CRISPR specificity
- Monitoring editing methods: Understanding and monitoring what is happening at the target site of editing
- Methods to define off-target effects of CRISPR/Cas9
- Harnessing bioinformatics

Led By:

Workshop Chairman:

TJ Cradick, Head of Genome Editing, CRISPR Therapeutics, USA

Eric Paul Bennett, Associate Professor, University of Copenhagen, Denmark